Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;42(6):e3239.
doi: 10.1002/hon.3239. Epub 2023 Dec 1.

Classic Hodgkin lymphoma

Justine Kahn  1 , Bouthaina Dabaja  2 , Susan Wu  2 , Kara Kelly  3 , Leanne Berkahn  4 , Astrid Pavlovsky  5 , Anna Sureda  6 , Ann LaCasce  7
Affiliations
Review

Classic Hodgkin lymphoma

Justine Kahn et al. Hematol Oncol. 2024 Nov.

Abstract

Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15-39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5-year overall survival (OS) approaching 90% today. [1](#ref-0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long-term outcomes. Despite continued improvements in up-front and salvage therapy, long-term survivors of HL experience several treatment-associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high-priority in the field.

Keywords: AYA; Hodgkin; lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Kahn JM, Kelly KM. Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care. Pediatr Blood Cancer. 2018;65(7):e27033. https://doi.org/10.1002/pbc.27033
    1. van Leeuwen FE, Ng AK. Long‐term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):323‐330. https://doi.org/10.1182/asheducation‐2016.1.323
    1. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved‐field radiation in early‐stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916‐1927. https://doi.org/10.1056/NEJMoa064601
    1. Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response‐adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786‐1794. https://doi.org/10.1200/JCO.2016.68.6394
    1. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET‐directed therapy for early‐stage Hodgkin's lymphoma. N Engl J Med. 2015;372(17):1598‐1607. https://doi.org/10.1056/NEJMoa1408648

LinkOut - more resources